Industrializing Electrophysiology: HT Automated Patch Clamp on SyncroPatch® 96 Using Instant Frozen Cells

  • Liudmila PolonchukEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1183)


Patch-clamping is a powerful technique for investigating the ion channel function and regulation. However, its low throughput hampered profiling of large compound series in early drug development. Fortunately, automation has revolutionized the area of experimental electrophysiology over the past decade. Whereas the first automated patch-clamp instruments using the planar patch-clamp technology demonstrated rather a moderate throughput, few second-generation automated platforms recently launched by various companies have significantly increased ability to form a high number of high-resistance seals. Among them is SyncroPatch® 96 (Nanion Technologies GmbH, Munich, Germany), a fully automated giga-seal patch-clamp system with the highest throughput on the market. By recording from up to 96 cells simultaneously, the SyncroPatch® 96 allows to substantially increase throughput without compromising data quality. This chapter describes features of the innovative automated electrophysiology system and protocols used for a successful transfer of the established hERG assay to this high-throughput automated platform.

Key words

SyncroPatch® 96 Automated patch clamp Drug discovery High throughput screening Electrophysiology hERG 



The author would like to thank the Nanion Technologies GmbH team, especially Drs. Andrea Brüggemann, Sonja Stoelzle, and Timo Stengel, for their help. I am also grateful to Drs. Claudia McGinnis and Thomas Weiser from Roche Non-Clinical Safety for supporting the acquisition and validation of the system, and to Evgenia Gissinger for technical assistance.


  1. 1.
    Möller C (2010) Impact of new technologies for cellular screening along the drug value chain. Drug Discov Today 15:384–390PubMedCrossRefGoogle Scholar
  2. 2.
    Scheel O, Himmel H, Rascher-Eggstein G et al (2011) Introduction of a modular automated voltage-clamp platform and its correlation with manual human Ether-à-go-go related gene voltage-clamp data. Assay Drug Dev Technol 9:600–607PubMedCrossRefGoogle Scholar
  3. 3.
    Donovan BT, Bakshi T, Galbraith SE et al (2011) Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and Nav1.5 blockade. J Pharmacol Toxicol Methods 64:269–276Google Scholar
  4. 4.
    Guthrie H, Livingston FS, Gubler U et al (2005) A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system. J Biomol Screen 10:832–840PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Roche Pharmaceutical Research and Early Development, Innovation Center BaselF. Hoffmann-La Roche Ltd.BaselSwitzerland

Personalised recommendations